Quantcast

Latest Leflunomide Stories

2014-06-10 23:13:54

Achieve is conducting a multicenter, randomized, single-dose study assessing the pharmacodynamic parameters of an experimental combination therapy in patients with rheumatoid arthritis on stable methotrexate (MTX) treatment. Birmingham, AL (PRWEB) June 10, 2014 *To see if you qualify for this RA Clinical Trial in Birmingham, visit Achieve Clinical Research on the web (http://www.achieveclinical.com/) or contact us directly at (205) 380-6434. There is no cost to participate, no insurance...

2013-09-24 23:39:05

Achieve is conducting a study to evaluate the safety and efficacy of a new drug versus rituximab in patients with moderately to severely active rheumatoid arthritis (RA). Birmingham, Alabama (PRWEB) September 24, 2013 *To see if you qualify for this RA Clinical Trial in Alabama, visit Achieve Clinical Research on the web (http://www.achieveclinical.com/) or contact us directly at (205) 380-6434. There is no cost to participate, no insurance is required, and you may receive compensation...

2013-03-07 23:51:30

26 countries can't afford certain disease modifying drugs, so excluding 320 million people This means that 320 million people - 40% of Europe's population - who could benefit from treatment with disease modifying drugs (DMARDs) would struggle to get access to them, say the researchers. DMARDs are extremely effective for the treatment of rheumatoid arthritis, and the European League Against Rheumatism (EULAR) recommends the use of synthetic DMARDs immediately after diagnosis to halt...

2012-06-08 13:33:04

New study validates score as new tool Results of a study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, suggest that the newly developed RABBIT Risk Score, which calculates the risk of serious infections in patients with rheumatoid arthritis (RA) who are treated with anti-tumor necrosis factor drugs (anti-TNFs) or conventional disease modifying anti-rheumatic drugs (DMARDs) is a valid and effective tool for rheumatologists to predict risk of...

2011-05-25 15:29:29

With an acceptable safety profile -- results of a separate study shows promising results in several patient subgroups, including DMARD non-responders Results of a Phase III study presented today at the EULAR 2011 Annual Congress show that at 6 months, 58.3 percent of patients who had previously not responded to treatment with DMARDs, achieved ACR20 response (a 20 percent improvement in symptoms) when treated with the novel oral Janus kinase inhibitor tofacitinib at 10mg BID compared to 31.2...

297a75031b4f955f9a66fe1df0fbd47e1
2011-03-24 05:55:00

A breakthrough discovery may offer an effective new treatment for melanoma, one of the deadliest forms of skin cancer, scientists said on Wednesday. The researchers found that leflunomide - a drug commonly used to treat rheumatoid arthritis "“ also inhibits the growth of malignant melanoma.  Furthermore, when leflunomide was used in combination with PLX4720, a promising new melanoma therapy currently undergoing clinical trials, the effect was even more powerful "“ leading to...

2010-06-18 14:20:41

The expression of a transporter protein called the Breast Cancer Resistance Protein (BCRP) in rheumatoid arthritis (RA) patients may indicate higher disease activity and could be a barrier to the effectiveness of disease-modifying antirheumatic drugs (DMARDs), according to the results of a study presented today at EULAR 2010, the Annual Congress of the European League Against Rheumatism in Rome, Italy. In a Turkish study, researchers analysed specimens of synovium (the soft tissue that lines...

2009-05-25 00:00:00

- Fifth International Phase III ACTEMRA Study Meets its Primary Endpoints - NUTLEY, N.J., May 25 /PRNewswire/ -- Roche today announced that two-year data from the LITHE (TociLIzumab Safety and THE Prevention of Structural Joint Damage) study demonstrated that ACTEMRA(R) (tocilizumab) continued to inhibit the progression of structural damage to joints in patients with rheumatoid arthritis (RA). The study also showed that patients receiving ACTEMRA experienced improved physical function, as...

2008-10-25 21:00:11

NUTLEY, N.J., Oct. 25 /PRNewswire/ -- One-year data from a two-year Phase III study demonstrated that ACTEMRA(R) (tocilizumab) significantly inhibited the progression of structural joint damage in patients with rheumatoid arthritis (RA). Late-breaking results from the LITHE study will be featured as an oral presentation during the American College of Rheumatology (ACR) Annual Scientific Meeting (October 24-28) in San Francisco. Fourteen additional abstracts, which evaluate ACTEMRA, a novel...


Latest Leflunomide Reference Libraries

2011-01-05 16:14:54

The BK virus, a member of the polyomavirus family, has no major consequences of infected except with those that are immunocomprimised or immunosuppressed. The virus was first isolated in 1971 from the urine sample of a renal transplant patient whose initials were B.K. Similar in genome sequences to the JCV virus they are most easily identified and differentiated from each other through serological tests using specific antibodies or through PCR based genotyping approach. Most people are...

More Articles (1 articles) »
Word of the Day
malpais
  • The ragged surface of a lava-flow.
'Malpais' translates from Spanish as 'bad land.'